Zynerba Pharmaceuticals (ZYNE - Free Report) closed the most recent trading day at $7.44, moving -0.53% from the previous trading session. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow added 0.42%, and the tech-heavy Nasdaq gained 0.56%.
Coming into today, shares of the specialty pharmaceutical company had lost 1.27% in the past month. In that same time, the Medical sector gained 6.43%, while the S&P 500 gained 4.42%.
Investors will be hoping for strength from ZYNE as it approaches its next earnings release. On that day, ZYNE is projected to report earnings of -$0.51 per share, which would represent a year-over-year decline of 8.51%.
Any recent changes to analyst estimates for ZYNE should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ZYNE is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 50, putting it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.